The healthcare AI pitch deck has become predictable. Slide three promises efficiency. Slide seven shows testimonials. Slide twelve projects market size. What's usually missing? Peer-reviewed proof that any of it works outside a controlled demo environment.
Laguna Health, a Tel Aviv-based startup building conversational AI for health insurance care managers, is trying something different. Instead of leaning on anecdotal wins and early-stage pilots, the company has published clinical trial results in academic journals and documented performance metrics from enterprise deployments. Whether that's enough to stand out in a crowded field is another question entirely—but at minimum, it's a departure from the norm.
The company raised a $15 million Series A round in May 2023, with an additional $4.1 million Series A extension recorded in January 2025, and has since focused its conversational AI tools specifically on payer care management teams, the often-overlooked workforce responsible for coordinating patient care after hospital discharge. Those teams, Laguna argues, represent a high-value opportunity: intensive, documentation-heavy work with measurable impact on readmissions and costs. Now, roughly three years into building, Laguna is pointing to something most AI health startups can't: data that's been through peer review.
The Academic Paper Trail
A randomized controlled trial published in the Journal of Healthcare Management in July 2023 examined personalized interventions for cardiovascular patients post-discharge. The single-center study showed measurable effects on patient experience and cost reduction linked to readmission rates. It's not a massive multi-site trial, but it's also more than most ambient AI vendors have produced in terms of formal clinical validation.
Laguna also contributed to research published earlier, in Population Health Management back in April 2021, identifying a familiar healthcare cost pattern: about 4% of hospitalized members in employer-sponsored plans account for 37% of total spending. The finding reinforces what the company has bet on—that the transition period immediately after hospital discharge is both high-stakes and expensive, a window where technology-assisted care coordination might actually make a difference.
The company has documented actuarial validation work, though those cost-impact models haven't been independently published and remain accessible only through gated downloads. Translation: interesting, perhaps useful internally, but not quite the same as open academic scrutiny.
Time Savings That (Supposedly) Hold Up
One case study, published around October 2025, tracked a deployment that started as a late-2024 pilot and expanded to over 300 users by the following spring. The headline figure: 66% average time savings on post-call documentation, coupled with what Laguna describes as "nearly 100% accuracy" in the clinical content generated.
That "nearly" matters. In healthcare, rounding errors can mean liability. The company emphasizes that its edge isn't just transcription—it's team-specific documentation calibrated to each care management group's protocols and quality standards. Unlike ambient scribes built for physicians entering notes into electronic health records, Laguna's tools are designed for the workflows of care managers, who operate under different regulatory and operational constraints.
The platform breaks into three pieces: Laguna Companion, which provides real-time call guidance; Laguna Insight, a dashboard for quality and performance tracking; and LISA, a workflow automation layer. Insight, notably, earned a spot on TIME's 2024 Best Inventions list in the healthcare worker support category. CB Insights also named Laguna to its Digital Health 50 in December 2024—recognitions that suggest at least some external validation beyond the company's own marketing.
Enterprise Adoption (or Something Close to It)
The clearest signal of traction might be the enGen partnership. enGen, the tech and operations division of health insurer Highmark, integrated Laguna's AI into its Predictal care management platform. By May 2025, the rollout had reached more than 300 case managers. An enGen article referencing that May milestone described efficiency improvements and documentation summaries that aligned closely with how managers actually worked.
In October 2024, Laguna announced a deal with Shearwater Health, a Nashville-based care management firm that chose Laguna for its first conversational AI deployment. That adoption matters, perhaps more than the founders expected: it signals interest not just from insurers managing their own populations, but from third-party firms providing care management as a service.
Laguna has also collaborated with Elevance Health (formerly Anthem) through the UCSF Rosenman ADAPT program, a relationship dating back to 2022. The company's website lists partnerships with NorthShore and Mayo Clinic, though details on those engagements remain sparse.
Toward Compliance Automation
In February 2026, Laguna announced an update to its Insight product, adding automated evaluations aligned to team-specific clinical and quality protocols. The shift moves the platform from passive dashboards—here's what happened—to what the company frames as "actionable intelligence," or tools that flag issues before they become audit problems. It's a direct play on NCQA and URAC standards, the regulatory frameworks governing payer care management, and a bet that compliance automation will prove stickier than productivity gains alone.
Laguna has raised north of $21 million to date: a $6.6 million seed round in May 2021 co-led by Pitango HealthTech and LionBird, and that $15 million Series A two years later, co-led by SemperVirens and HC9 Ventures. Deal databases also show a $4.1 million Series A extension recorded in January 2025, though the company hasn't made a public announcement about that capital.
The Moat Question
Laguna is positioning itself outside the ambient scribe market dominated by Abridge, Nuance DAX, and others focused on physician documentation. Instead, it's targeting payer workflows, quality monitoring, and compliance—domains where regulatory pressure and cost accountability arguably matter more than sheer speed.
Whether that focus translates into defensible differentiation is harder to say. Care management teams aren't as large or visible as physician practices, and payer organizations can be slow to adopt and even slower to expand pilots into full deployments. But Laguna has assembled something relatively rare in the AI health space: published research, actuarial backing (however gated), and enterprise users beyond the proof-of-concept stage.
For a field drowning in promises, that might count as proof. Or at least, the beginning of it.
